Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Abbott Laboratories Narrows FY2025 Adj EPS Guidance from $5.10-$5.20 to $5.12-$5.18 vs $5.15 Est

Author: Benzinga Newsdesk | October 15, 2025 06:33am

ABBOTT'S FINANCIAL GUIDANCE

Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales. Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint.

Posted In: ABT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist